SNN Smith & Nephew SNATS Inc

Deprince Race & Zollo Inc. significantly reduced its stake in Smith & Nephew (NYSE:SNN) by 37.3% in the third quarter of 2025, selling over 200,000 shares. Despite this, institutional investors and hedge funds still collectively own 25.64% of the stock. Analysts have a consensus "Hold" rating for SNN, with an average price target of $35.75, following mixed recent analyst actions including a downgrade from RBC and an upgrade from Kepler.

Smith & Nephew plc currently has a high price-to-earnings (P/E) ratio of 28.6x, significantly above the UK market average, which could indicate bearish signals. However, this elevated P/E is supported by the company's strong recent earnings growth of 61% and a projected 25% annual earnings growth for the next three years, outpacing the broader market forecast. Investors appear to be willing to pay a premium for the stock due to these strong future growth expectations.

The Wound Debridement Products Market is projected to grow at a CAGR of 5.9% from 2024 to 2031, driven by increasing demand for advanced wound care solutions. This market includes medical devices, dressings, and solutions for removing dead or infected tissue to promote faster healing and reduce infection risks. Key players such as B. Braun Melsungen AG, Smith & Nephew, and ConvaTec Group are prominent in this sector, with recent developments focusing on product innovation and manufacturing capacity expansion across North America and Europe.

Smith & Nephew plc (LON:SN.) has a high P/E ratio of 28.6x, significantly above the United Kingdom market average. This elevated P/E is supported by the company's strong recent earnings growth of 61% and an analyst forecast of 25% annual EPS growth over the next three years, outpacing the broader market's 15% forecast. Investors appear to expect continued strong performance, justifying the premium valuation.

Smith & Nephew SNATS (NYSE:SNN) was downgraded from a "strong-buy" to a "buy" rating by Wall Street Zen. The company currently holds a consensus "Hold" rating from analysts with an average target price of $35.75. Shares opened at $32.81, trading below its 50- and 200-day moving averages, while institutional investors own approximately 25.64% of the stock.

Eight analysts covering Smith & Nephew SNATS, Inc. (NYSE:SNN) have issued a consensus "Hold" rating, with an average 12-month target price of $35.75. Recent analyst actions show mixed sentiment, including a downgrade by Royal Bank of Canada and upgrades to "strong-buy" by Kepler Capital Markets and Wall Street Zen. The company's stock shows institutional ownership of 25.64% and trades within a 52-week range of $23.69–$38.79.